Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Jonathon B. Cohen, Daniel M Guidot, Joseph Maly, Jeffrey M. Switchenko, Loretta J. Nastoupil, Jean L. Koff, Christopher R. Flowers, Kristie A. Blum
Publikováno v:
Leukemia & Lymphoma. 59:888-895
Mantle cell lymphoma (MCL) is a heterogeneous disease with high relapse rates. Limited data guide the use of surveillance imaging following treatment. We constructed a retrospective cohort from two academic institutions of patients with MCL who compl
Autor:
Mark W, Clemens, L Jeffrey, Medeiros, Charles E, Butler, Kelly K, Hunt, Michelle A, Fanale, Steven, Horwitz, Dennis D, Weisenburger, Jun, Liu, Elizabeth A, Morgan, Rashmi, Kanagal-Shamanna, Vinita, Parkash, Jing, Ning, Aliyah R, Sohani, Judith A, Ferry, Neha, Mehta-Shah, Ahmed, Dogan, Hui, Liu, Nora, Thormann, Arianna, Di Napoli, Arianna, DiNapoli, Stephen, Lade, Jorge, Piccolini, Ruben, Reyes, Travis, Williams, Colleen M, McCarthy, Summer E, Hanson, Loretta J, Nastoupil, Rakesh, Gaur, Yasuhiro, Oki, Ken H, Young, Roberto N, Miranda
Publikováno v:
Journal of Clinical Oncology. 34:160-168
Purpose Breast implant–associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate
Autor:
Jason R. Westin, Amy Rich, Francesco Turturro, Chao Ming Lai, Sarah A. Milgrom, Yasuhiro Oki, Nathan Fowler, Peter McLaughlin, Chan Yoon Cheah, Michael L. Wang, Loretta J. Nastoupil, Sandra B. Horowitz, Felipe Samaniego, Jorge E. Romaguera, Luis Fayad, Bouthaina S. Dabaja, Chelsea C. Pinnix, L. Jeffrey Medeiros, Michelle A. Fanale, Maria Alma Rodriguez, Hun J. Lee, Anas Younes, Fredrick B. Hagemeister, Sattva S. Neelapu
Publikováno v:
Blood. 130(4)
Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transf
Autor:
Leon Bernal-Mizrachi, Jean L. Koff, Rajni Sinha, Nassoma King, Miray Seward, Sagar Lonial, Pareen J. Shenoy, Christopher R. Flowers, Amelia Langston, Mary Jo Lechowicz, Alexander J. Ambinder, Edmund K. Waller, Ajay K. Nooka, Loretta J. Nastoupil, Jonathan L. Kaufman
Publikováno v:
Leukemia & Lymphoma. 56:383-389
Mantle cell lymphoma (MCL) remains incurable with conventional chemotherapy without consensus on the optimal initial treatment. We examined our single center experience with frontline therapy for patients with MCL in consecutive cases diagnosed 1995-
Autor:
Francesco Turturro, Jason R. Westin, L. J. Medeiros, Jorge E. Romaguera, Yasuhiro Oki, Luis Fayad, Hun J. Lee, Long Ma, Felipe Samaniego, Richard E. Davis, Maria Alma Rodriguez, Loretta J. Nastoupil, Chelsea C. Pinnix, Mansoor Noorani, Nathan Fowler, Sattva S. Neelapu, Larry W. Kwak, Michael Wang, Pei Lin, Yago Nieto, Bouthaina S. Dabaja, Mohamed Amin Ahmed, Fredrick B. Hagemeister, Issa F. Khouri, Michelle A. Fanale
Publikováno v:
British Journal of Haematology. 166:891-901
Summary We report our experience with 129 cases of double hit lymphoma (DHL), defined as B-cell lymphoma with translocations and/or extra signals involving MYC plus BCL2 and/or BCL6. All cases were reviewed for histopathological classification. Media
Autor:
Chitra Hosing, Fredrick B. Hagemeister, Jorge E. Romaguera, Jason R. Westin, Michael Wang, Felipe Samaniego, Sattva S. Neelapu, Mansoor Noorani, Loretta J. Nastoupil, Nathan Fowler, Francesco Turturro, Luis Fayad, Roberto N. Miranda, Yago Nieto, L. Jeffrey Medeiros, Yasuhiro Oki, M. Alma Rodriguez, Michelle A. Fanale, Dai Chihara, Hun J. Lee, Richard E. Davis
Summary Survival outcome of patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) who experience disease progression/relapse remains very poor. A total of 321 patients, newly diagnos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d8d25a57ebb8aad3672fac9af9c914
https://europepmc.org/articles/PMC5836501/
https://europepmc.org/articles/PMC5836501/
Autor:
Kun Jiang, Xiaojing Wang, Satya Das, Mohammad K. Khan, Christopher R. Flowers, Zheng Shi, Natia Esiashvili, Zhengjia Chen, Derick Okwan-Duodu, Loretta J. Nastoupil
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 86:569-577
The role of consolidative radiation therapy (RT) after complete response (CR) to rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for stage III-IV diffuse large B-cell lymphoma (DLBCL) patients is unclear. W
Autor:
Amanda Hutchison-Rzepka, Jonathan L. Kaufman, Sagar Lonial, Jean L. Koff, Jonathon B. Cohen, Rajni Sinha, Christopher R. Flowers, Amanda Colbert, Amelia Langston, Mary Jo Lechowicz, Leonard T. Heffner, Nassoma Bumpers, H. Jean Khoury, Jeffrey M. Switchenko, Loretta J. Nastoupil
Bortezomib-containing combinations are active in non-Hodgkin lymphoma (NHL) although peripheral neuropathy can limit their dose intensity. Based on our phase I findings, we conducted a phase II trial of bortezomib in combination with R-CHOP (rituxima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d3dc5b19bf699eb1a02aeddea67b79
https://europepmc.org/articles/PMC4626332/
https://europepmc.org/articles/PMC4626332/
Autor:
Sattva S. Neelapu, Loretta J. Nastoupil, Francesco Turturro, Larry W. Kwak, Yasuhiro Oki, Seema Rawal, Robert Z. Orlowski, Jatin P. Shah, R. Eric Davis, Veerabhadran Baladandayuthapani, Kenneth Y. Tsai, Fredrick B. Hagemeister, Michelle A. Fanale, Linda Claret, Peter McLaughlin, Felipe Samaniego, Lei Feng, Nathan Fowler, Tariq Muzzafar, Jason R. Westin, Jorge E. Romaguera, Luis Fayad, Michael Wang
Summary Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma. We asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e7d38c79178443881dcfc20c3e6dda
https://europepmc.org/articles/PMC4370362/
https://europepmc.org/articles/PMC4370362/
Autor:
Andre Goy, Eric P. Winer, Rajneesh Nath, Chadi Nabhan, Ted Feldman, Andrew M. Evens, Aimee R. Kroll-Desrosiers, Frederick Lansigan, Deepa Jagadeesh, Lori Muffly, Loretta J. Nastoupil, Christopher R. Flowers, Bruce A. Woda, Jorge J. Castillo, Sonali M. Smith, Jeremy S. Abramson, Steve Rosen
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(11)
Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear.We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matc